logo
Suki Waterhouse Says She ‘Wore Pants So Tight' They ‘Caused a Hernia'

Suki Waterhouse Says She ‘Wore Pants So Tight' They ‘Caused a Hernia'

Yahoo4 days ago
Tight pants are annoying, uncomfortable and anything but desirable, but a celebrity recently claimed they're downright dangerous, too.
Earlier this week, actress and singer Suki Waterhouse posted a tweet claiming that she got a hernia from wearing too-tight pants.
For anyone who's ever zipped up a pair of jeans that are a little too small, this may come as a shock. Do those too-tight pants put you at risk of a hernia?
Here's what doctors say:
What is a hernia?
A hernia is 'a weakness in the abdominal wall that allows something from the abdomen to protrude through the layers of the abdominal wall,' said Dr. Brittany Mead, an assistant professor of surgery at Rush University Medical Center in Chicago.
'It's a fancy word for a hole in the human body,' added Dr. Eric Wise, an assistant professor of surgery at the University of Minnesota Medical School.
Tissue — such as fats, organs or intestines — that isn't supposed to protrude through ends up poking through, Wise added.
This often creates a bulge in your abdomen or groin, but it isn't always visible, Wise noted.
It can sometimes cause pain, Mead said. But this also isn't always the case.
Many things can cause a hernia.
'Many things can cause a hernia, and most are beyond our control,' said Wise.
They can happen after trauma and after surgery. Certain things present at birth can increase someone's risk of developing it, too, he added.
But there are some risk factors that we do have control over, added Mead.
'Things like chronic cough, obesity, pregnancy and lots of strenuous exercise can increase risk of hernia,' Mead said. Constipation can also increase your risk.
Quitting smoking, managing your weight and avoiding constipation by eating a high-fiber diet are all ways to reduce your risk of getting a hernia, added Wise.
'But oftentimes, hernias are unavoidable,' Wise said. Meaning, you won't totally erase the chance of developing a hernia by doing these things.
One thing that won't cause a hernia? Wearing tight pants.
Sorry to Suki, but tight pants likely weren't the reason for the hernia. It's 'not something that you're going to do by wearing the wrong piece of clothing one time,' Mead said.
So no, a pair of tight pants is not going to be the sole reason you end up with a hernia. And that's true even if you wear tight pants regularly for years and years.
Wise agreed. 'Up front, obviously, I don't know about her specific medical condition and don't know the details, but in my practice, I have never seen or are familiar with a case of tight pants causing a hernia,' said Wise.
Wise added that he also can't think of a 'plausible physiologic mechanism by which that can happen.'
The tight pants may have exacerbated any pain associated with an existing hernia by squeezing the abdominal area, but the tight pants wouldn't cause a hernia on their own, Wise added.
It's even more unlikely that the tight pants caused the hernia for another reason.
'In a lot of patients, we actually recommend... that they wear an abdominal binder or a waist trainer, which actually puts pressure on the hernia and kind of controls the protuberance of that intra-abdominal tissue,' said Mead.
'So, wearing tight pants would act in a very similar way,' she said.
While Mead stressed that she, of course, can't comment specifically on Waterhouse's specific health situation, Waterhouse had a baby in March 2024 and 'that's something that would make me feel like [the hernia] was related more to the pregnancy than anything else,' Mead noted.
Worrying about developing a hernia isn't worth it — live your life and if you develop one, see a doctor.
When it comes to decreasing your chance of developing a hernia, you shouldn't worry too much.
'What I tell my patients specifically is, especially if they don't have a hernia, that they should live their life,' said Mead.
Some studies say family history could put you at heightened risk of hernia, but Mead said she doesn't advise against any behaviors — 'we don't have enough research to say that one activity over another is going to cause a hernia that doesn't exist.'
'I don't specifically advise my patients against any type of activity. I want them to live their lives, and if they form a hernia, they form a hernia,' she added.
'If you see a bulge or feel a bulge or feel like something's not right, I think it's reasonable to have a physician examine the area,' said Wise. That can be your primary care provider or a specialist such as a general surgeon, he added.
Hernia management and treatment have advanced significantly in the past decade or so, said Wise.
'While not every hernia needs surgery, it's certainly something that is best evaluated by a physician, and the main things that can be done to prevent it are lifestyle modifications and not necessarily changing your wardrobe,' Wise added.
Related...
7 Signs Your Gas Or Bloating Is A Bigger Issue
Lupita Nyong'o Revealed She Has Painful Uterine Fibroids. Here's What That Means.
I'm A Gastro Doctor. Here's The 1 Thing I'd Never Do If I Had Stomach Pain.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

Yahoo

time24 minutes ago

  • Yahoo

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, July 22, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. "As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives," said Maria Zannes, President and CEO of bioAffinity Technologies. Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking. "We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science," Ms. Zannes said. "Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics." The Canadian patent (Patent No. 3,136,245) – titled "System and Method for Determining Lung Health" – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Investor Relations Dave GentryRedChip Companies Inc.1-800-RED-CHIP (733-2447) or 407-491-4498BIAF@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings
Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings

Yahoo

time24 minutes ago

  • Yahoo

Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings

July 22 - UnitedHealth Group (NYSE:UNH) has tumbled roughly 42% year?to?date, driven by rising Medicare Advantage costs, a surprise CEO exit, withdrawn guidance and a Department of Justice probe. However, ahead of its July 29 Q2 earnings, Bernstein analyst Lance Wilkes tapped UNH as a 'Top Pick,' saying the pullback creates an attractive entry point. He noted the stock trades at about 13.5 times forward earnings, below its ten?year average. Warning! GuruFocus has detected 4 Warning Sign with UNH. Wilkes cut his 2025 EPS estimate by 10% to reflect reserve strengthening and cost pressures in individual and Medicaid segments, plus a cleanup of OptumHealth risk contracts. Yet he projects earnings per share could double by 2029, implying a 19% compound annual growth rate. The analyst expects cost normalization to begin in Medicaid in Q3 and in Medicare Advantage in early 2026 as utilization patterns stabilize. He also highlighted a hardening pricing environment for government managed?care plans as a margin tailwind. Is UNH Stock a Buy? Based on the one year price targets offered by 24 analysts, the average target price for UnitedHealth Group Inc is $375.46 with a high estimate of $677.00 and a low estimate of $270.00. The average target implies a upside of +33.08% from the current price of $282.14. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025
Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025

Yahoo

time24 minutes ago

  • Yahoo

Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025

MINNEAPOLIS, July 22, 2025--(BUSINESS WIRE)--Sleep Number Corporation (Nasdaq: SNBR) will release its fiscal second quarter results through June 28, 2025, before market open on Wednesday, July 30, 2025. Management will host its regularly scheduled conference call to discuss the company's results at 8:30 a.m. EDT (7:30 a.m. CDT; 5:30 a.m. PDT). To access the webcast, please visit the investor relations area of the Sleep Number website at The webcast replay will remain available for approximately 60 days. About Sleep Number Corporation Sleep Number is a sleep wellness company. We are guided by our purpose to improve the health and wellbeing of society through higher quality sleep. To date, our innovations have improved nearly 16 million lives. Our sleep wellness platform helps solve sleep problems, whether it's providing individualized temperature control for each sleeper through our Climate360 smart bed or applying our 34 billion hours of longitudinal sleep data and expertise to research with global institutions. Our smart bed ecosystem helps people sleep better by offering adjustable comfort and personalized sleep and health insights. Millions of Smart Sleepers benefit from higher quality sleep, and our 3,400 dedicated team members are passionate about creating innovative solutions through our vertically integrated business model, including direct-to-consumer selling in 630 stores and online. To learn more about life-changing, individualized sleep, visit a Sleep Number® store near you, our newsroom and investor relations sites, or View source version on Contacts Investor Contact investorrelations@ Media Contact Muriel Lussier, Sleep Number Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store